WAKAMOTO PHARMACEUTICAL CO., LTD. – Trademark Portfolio
Entity Type: 03
WAKAMOTO PHARMACEUTICAL CO., LTD. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include MAQAID, OPETRIA, and WAKAMOTO.
2-2, Nihonbashi Honcho 2-chome,
Chuo-ku; Tokyo 103-8330
Showing of trademarks Trademarks
Trademark Classifications
WAKAMOTO PHARMACEUTICAL CO., LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does WAKAMOTO PHARMACEUTICAL CO., LTD. have?
WAKAMOTO PHARMACEUTICAL CO., LTD. has 8 U.S. trademarks filed with the USPTO. Of these, 4 registered, 3 cancelled.
What trademark classes does WAKAMOTO PHARMACEUTICAL CO., LTD. file in?
WAKAMOTO PHARMACEUTICAL CO., LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are WAKAMOTO PHARMACEUTICAL CO., LTD.'s most well-known trademarks?
WAKAMOTO PHARMACEUTICAL CO., LTD.'s registered trademark portfolio includes well-known marks such as MAQAID, OPETRIA, and WAKAMOTO. These are among 4 currently registered trademarks in the portfolio.
What is WAKAMOTO PHARMACEUTICAL CO., LTD.'s trademark registration success rate?
WAKAMOTO PHARMACEUTICAL CO., LTD. has a 57% trademark registration rate, with 4 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.